Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
GlaxoSmithKline, Sanofi post positive mid-stage trial results for COVID-19 vaccine
02:30am, Monday, 17'th May 2021
GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi demonstrated strong immune responses in mid-stage trials. The jab showed 95% to 100% seroconversion
Sanofi and Glaxo Are Back With a Covid-19 Vaccine
01:30am, Monday, 17'th May 2021
The two drugmakers say it might be most useful as a booster shot.
Is Sanofi a Good Buy in 2021?
06:20am, Wednesday, 12'th May 2021
You might want to add this international blue-chip stock to your portfolio.
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
01:00am, Thursday, 06'th May 2021
PARIS and PALO ALTO, Calif., May 6, 2021 /PRNewswire/ -- Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine.
Sanofi (SNY) CEO Paul Hudson on Q1 2021 Results - Earnings Call Transcript
12:45am, Thursday, 29'th Apr 2021
Sanofi (SNY) CEO Paul Hudson on Q1 2021 Results - Earnings Call Transcript
Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran
01:27pm, Wednesday, 28'th Apr 2021
Sanofi SA (NASDAQ: SNY) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its delayed COVID-19 vaccine efforts. Ea
Update: 91 'Top Dividend Stocks On Earth' For May
01:18pm, Wednesday, 28'th Apr 2021
Kiplinger "insights for investors" online first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 4/26/21 flagged 13 yields ripe with upside. These Intern
Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View
12:17pm, Wednesday, 28'th Apr 2021
Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.
Sanofi Beats Earnings Estimates and Reveals Covid-19 Vaccine Progress
07:03am, Wednesday, 28'th Apr 2021
The French pharma giant, which has fallen behind in the Covid-19 vaccine race, said results from a Phase 2 study into its candidate with GlaxoSmithKline are expected next month.
Eczema treatment and vaccines lift Sanofi first quarter results
03:11am, Wednesday, 28'th Apr 2021
Sanofi confirmed its 2021 targets after it posted stronger-than-expected first quarter results as sales of its star eczema treatment as well as flu and polio vaccines helped offset a dip in cough and
Sanofi Steps In For Fill-Finish 200M Doses Of Moderna's COVID-19 Vaccine
09:18am, Monday, 26'th Apr 2021
As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY) has entered an agreement with Moderna Inc (NASDAQ: MRNA) to manufacture its COVID-19 vaccine in the U.S. The ag
Moderna Receives Vaccine-Making Boost As Sanofi Signs Up To Manufacture 200 Million Doses For Americans
08:52am, Monday, 26'th Apr 2021
The shots could be geared towards children, new variants or boosters.
Sanofi agrees to make Moderna COVID-19 vaccine in the U.S. starting in September
07:13am, Monday, 26'th Apr 2021
French drug maker Sanofi S.A. has agreed to make Moderna Inc.'s COVID-19 vaccine at its site in Ridgefield, New Jersey, and will fill and finish up to 200 million doses starting in September.
Sanofi-AstraZeneca's Nirsevimab Hits Primary Endpoint Goal In Late-Stage RSV Disease In Infants
06:16am, Monday, 26'th Apr 2021
Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc's (NASDAQ: AZN) monoclonal antibody (mAb) nirsevimab has reached its primary endpoint in a Phase 3 trial, demonstrating protection against respirator
Wide-Moat Stocks On Sale - The May 2021 Heat Map
01:31pm, Friday, 23'rd Apr 2021
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). e are only interested in those targets that are attractively valued in historical comparison.
